Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.00333-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Ji Hyun Yun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Sout…. Hauptthemen laut MEDLINE: Vancomycin, Bacteremia, Treatment Failure, Staphylococcal Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare (MOHW).
Abstract (Originalsprache)
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older ( P < 0.001) and more frequently had solid cancer ( P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent ( P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index ( P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores ( P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) ≤ 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia. IMPORTANCE In this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, South Korea.
- Division of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Center for Antimicrobial Resistance and Microbial Genetics, University of Ulsan College of Medicine, Seoul, South Korea.
ORCID-Profile: Ji Hyun Yun, Yong Pil Chong, Sang-Oh Lee, Yang Soo Kim
Förderung
- Ministry of Health and Welfare (MOHW)
Zitieren
APA
Yun, J. H., Chang, E., Bae, S., Jung, J., Kim, M. J., Chong, Y. P., Kim, S. H., Choi, S. H., Lee, S. O., & Kim, Y. S. (2024). Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00333-24
Vancouver
Yun JH, Chang E, Bae S, Jung J, Kim MJ, Chong YP, et al. Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00333-24
BibTeX
@article{Yun2024,
author = {Yun, Ji Hyun and Chang, Euijin and Bae, Seongman and Jung, Jiwon and Kim, Min Jae and Chong, Yong Pil and Kim, Sung-Han and Choi, Sang-Ho and Lee, Sang-Oh and Kim, Yang Soo},
title = {Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.00333-24}
}
EUVIMED